Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

Jul

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Amit Sanyal, MD: A Clinician’s Perspective

Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies

FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer

MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era

Global Breast Cancer Survival Estimates: WHO Analysis

Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer